文献速递心律失常

≥75岁持续性房颤患者:起搏器植入加房室结消融对比肺静脉隔离

Pacemaker-implantation and atrioventricular-node ablation vs pulmonary vein isolation for elderly patients with persistent atrial fibrillation: the ABLATE versus PACE trial.
PubMed 文献 · Eur Heart J · 2026-08-31

这项多中心开放标签试验纳入196例≥75岁有症状的持续性房颤且左室射血分数正常的患者,随机接受起搏器植入加房室结消融或肺静脉隔离。12个月时,起搏器植入加房室结消融组主要终点事件发生率低于肺静脉隔离组。

要点

  • ≥75岁有症状持续性房颤患者中,起搏器植入加房室结消融较肺静脉隔离减少12个月主要终点事件
  • 主要终点包括房性心律失常或心衰住院、门诊电复律及因左室功能不全升级心脏再同步化治疗
  • 两组心血管并发症、死亡率及生活质量无统计学差异

核心结论

  • 在≥75岁持续性房颤患者中,起搏器植入加房室结消融较肺静脉隔离在12个月随访期间主要终点事件更少

研究设计与样本

  • 研究类型为研究者发起的多中心开放标签随机试验,12个中心位于德国和奥地利
  • 共纳入196例≥75岁有症状的持续性房颤且左室射血分数正常的患者,随机分配至起搏器植入加房室结消融或肺静脉隔离
  • 中位年龄为82岁,12个月时分析主要终点

主要发现

  • 12个月时,起搏器植入加房室结消融组98例患者中24例发生首次主要终点事件,肺静脉隔离组98例中45例发生
  • 两组首次主要终点事件风险比0.45,95%置信区间0.27至0.74,P=0.002
  • 起搏器植入加房室结消融组共发生29次主要终点事件,肺静脉隔离组共发生84次
  • 肺静脉隔离组主要终点事件以房颤住院54次和电复律19次为主,起搏器植入加房室结消融组分别为3次和1次
  • 起搏器植入加房室结消融组心衰住院23次,肺静脉隔离组心衰住院11次

关键数值与推荐

  • 入组患者年龄≥75岁,有症状的持续性房颤,左室射血分数正常
  • 主要终点为房性心律失常或心衰住院、门诊电复律或因左室功能不全升级至心脏再同步化治疗的复合终点
  • 次要终点包括全因死亡、卒中、治疗相关并发症及生活质量

临床怎么用

  • 对≥75岁有症状的持续性房颤患者,起搏器植入加房室结消融可作为减少房性心律失常住院和电复律的策略选择
  • 起搏器植入加房室结消融组心衰住院次数较多,临床选择时需个体化评估

局限性

  • 开放标签设计,随访时间仅12个月
  • 起搏器植入加房室结消融组心衰住院较肺静脉隔离组更多,需进一步关注

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Population aging is increasing atrial fibrillation (AF) prevalence. In elderly patients with persistent AF, pulmonary-vein isolation (PVI) has limited success, but is widely used. Pacemaker-implantation with atrioventricular-node ablation (PM+AVNA) provides effective symptom control, but the relative effects of PM+AVNA versus PVI on hospitalisations and other outcomes in the elderly remain unknown. METHODS: This investigator-initiated, multicentre, open-label trial randomised patients aged≥75 years with symptomatic persistent AF and normal left-ventricular ejection fraction to PM+AVNA or PVI treatment-strategies. The primary endpoint was a composite of hospitalisation for atrial arrhythmia or heart failure, outpatient electrical cardioversion or upgrade to cardiac resynchronisation therapy for left-ventricular dysfunction. Secondary endpoints included all-cause death, stroke, treatment-related complications and quality of life. RESULTS: Twelve centres in Germany and Austria randomised 196 patients (median age 82 years). At 12 months, a first primary endpoint event occurred in 24 of 98 patients (24%) assigned to PM+AVNA and 45 of 98 patients (46%) assigned to PVI (hazard ratio 0.45, 95% confidence interval 0.27 to 0.74; P=0.002). A total of 29 and 84 primary endpoint events occurred respectively, consisting principally of AF-hospitalisations and cardioversions in the PVI group (54 and 19 respectively, vs 3 and 1 in PM+AVNA group) and of heart failure-hospitalisations in the PM+AVNA Group (23, vs 11 in PVI group). The incidence of cardiovascular complications and mortality, as well as qualityof-life, were not statistically different. CONCLUSIONS: In elderly patients with persistent AF, PM+AVNA was associated with fewer primary endpoint events than PVI over a 12-month follow-up period.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Boehmer, Eckardt, Rothe, et al. Pacemaker-implantation and atrioventricular-node ablation vs pulmonary vein isolation for elderly patients with persistent atrial fibrillation: the ABLATE versus PACE trial. Eur Heart J. 2026. PMID: 42671117. doi:10.1093/eurheartj/ehag742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。